Michael Shetzline Sells 41,269 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ironwood Pharmaceuticals Trading Up 3.6 %

NASDAQ IRWD opened at $2.01 on Friday. The stock’s 50 day moving average is $3.60 and its two-hundred day moving average is $4.17. The company has a market capitalization of $321.66 million, a price-to-earnings ratio of -67.00 and a beta of 0.29. Ironwood Pharmaceuticals, Inc. has a 1-year low of $1.59 and a 1-year high of $15.70.

Analyst Ratings Changes

Several equities analysts recently issued reports on IRWD shares. JMP Securities lowered their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday, January 30th. Craig Hallum lowered their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Finally, StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV boosted its holdings in Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $47,000. Envestnet Asset Management Inc. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000. Finally, Xponance Inc. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.